Ironwood Pharma (IRWD) Misses Q2 EPS by 4c, Revenues Miss; Offers 2018 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Ironwood Pharma (IRWD) Misses Q2 EPS by 4c, Revenues Miss; Offers 2018 Guidance

Ironwood Pharmaceuticals Provides Second Quarter 2018 Investor Update

August 6, 2018 8:00 AM EDT

Second quarter revenue increased 25% year-over-year to $81 million, driven primarily by LINZESS® (linaclotide) U.S. net sales of $192 million and commercial margin of 60%

Terminating licensing agreement with AstraZeneca for U.S. lesinurad franchise

Initiated Phase III programs with IW-3718 and linaclotide and advanced four Phase II trials with lead sGC stimulators, praliciguat and olinciguat

On track to complete separation of Ironwood into two independent, publicly traded companies in first half 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More